SMFM: No Benefit to Limiting Pregnancy Weight Gain in Obese

Share this content:
SMFM: No Benefit to Limiting Pregnancy Weight Gain in Obese
SMFM: No Benefit to Limiting Pregnancy Weight Gain in Obese

FRIDAY, Jan. 27, 2017 (HealthDay News) -- Strategies to help overweight or obese women limit their weight gain during pregnancy don't seem to alleviate the risk for obstetric complications, according to a study presented at the annual meeting of the Society for Maternal-Fetal Medicine, The Pregnancy Meeting, held from Jan. 23 to 28 in Las Vegas.

Researchers from Northwestern University randomly assigned 281 pregnant women who were overweight or obese to receive either typical obstetric care, or to receive additional help to limit the amount of weight they gained during pregnancy. This intervention included guidance from a dietitian, guidance on physical activity, and internet-based self-monitoring of eating habits.

According to the researchers, the intervention did work in one respect: The women gained much less weight during their pregnancy than the women who underwent routine care. However, this additional care was not linked to a drop in pregnancy-related complications, such as gestational hypertension, gestational diabetes, and large-for-gestational-age infants. There was also a higher rate of cesarean sections among the women in the intervention group.

"While pregnant women should still be counseled against excess weight gain, additional measures may be required to reduce the associated complications," lead author Alan Peaceman, M.D., chief of maternal-fetal medicine in the department of obstetrics and gynecology at Northwestern Medicine in Chicago, said in a meeting news release.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »